Дослідження зрозуміло

Назад до стрічки
PubMed

30 жовт. 2026 р.

Beyond the Black Box: Physics-Based and Conservation-Informed Evidence for ACVRL1 Variant Classification in Hereditary Haemorrhagic Telangiectasia and Pulmonary Arterial Hypertension.

Відкрити першоджерело

Чому це важливо

This research could enhance understanding of genetic testing results for patients with hereditary haemorrhagic telangiectasia and pulmonary arterial hypertension. It offers a better method to identify potentially harmful variants, which may influence treatment decisions. Patients might want to discuss these findings with their healthcare providers as new approaches in genetic testing evolve.

Мета

The study aims to improve how we classify genetic changes (variants) in the ACVRL1 gene, which is linked to hereditary haemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension. This is important because some variants are not clearly understood, making it difficult to know if they are harmful or not.

Результати

The new models achieved high accuracy in classifying variants, with scores nearly equivalent to AlphaMissense, which is one of the best tools available for this purpose. However, the models faced challenges with benign variants, which highlighted some limitations.

Методи

Researchers examined 899 ACVRL1 variants by evaluating their protein stability, conservation (how genetically similar a feature is across species), and structure. They created computer models to classify these variants based on 311 well-documented cases and compared their effectiveness to existing classifiers such as AlphaMissense.

Обмеження

The study relies on a computer modelling approach and uses previously classified variants for validation. This means it may not cover all types of variants or situations. It also depends on existing databases and knowledge, so the classifications should be considered as hypotheses that require further testing, rather than definitive evidence.

Для вашого лікаря:

PMID: 43027989

DOI: 10.3390/ijms27219742

Анотація

Показано англійською

Missense variants in ACVRL1 (ALK1) cause hereditary hemorrhagic telangiectasia type 2 (HHT2), heritable pulmonary arterial hypertension (PAH), or both in the same patient, and many remain variants of uncertain significance. AlphaMissense classifies them accurately but does not show which evidence drives a call. I annotated 899 ACVRL1 missense variants with protein-stability estimates (FoldX, DynaMut2), a GREMLIN-style conservation score, and structural context. I then trained random-forest classifiers on 311 variants with labels traceable to ClinVar or a publication (296 pathogenic-like, 15 benign-like). A structural/conservation-only classifier (Model 1b) reached a cross-validated ROC-AUC of 0.954 (95% CI 0.916-0.984), and a model adding sequence-based predictors (Model 1) reached 0.979, versus 0.983 for AlphaMissense on the same variants. On variants first reported in 2025-2026, Model 1b scored 0.976, Model 1 0.992, and AlphaMissense 0.992; equivalence within ±0.05 AUC was supported for Model 1 only. Benign variants were the main weakness: Model 1b correctly classified 10/15, against 14/15 for AlphaMissense. Conservation drove most calls, with predicted destabilization contributing to a minority. An interpretable, gene-specific classifier can approach AlphaMissense for ACVRL1 while showing the structural or evolutionary evidence behind each call. Its calls are hypotheses, not functional evidence, and can prioritize VUS for functional testing.